Table 4 Uptake-rate of the different products according to population and year of the analysis
Year 1 | Year 2 | Year 3 | |
|---|---|---|---|
Paediatrics | |||
rFVIIIFc | 10% | 15% | 20% |
Advate® | 27% | 25.5% | 24% |
Kogenate® | 26.1% | 24.7% | 23.2% |
Refacto® | 20.7% | 19.6% | 18.4% |
Helixate® | 15.3% | 14.5% | 13.6% |
Recombinate® | 0.9% | 0.9% | 0.8% |
Plasma-derived products | – | – | – |
Adults | |||
rFVIIIFc | 10% | 15% | 20% |
Advate® | 21.6% | 20.4% | 19.2% |
Kogenate® | 20.7% | 19.6% | 18.4% |
Refacto® | 16.2% | 15.3% | 14.4% |
Helixate® | 11.7% | 11.1% | 10.4% |
Recombinate® | 0.9% | 0.9% | 0.8% |
Plasma-derived products | 18.9% | 17.9% | 16.8% |